264 Participants Needed

GAE with Embosphere Microspheres for Knee Osteoarthritis

(MOTION Trial)

Recruiting at 36 trial locations
RA
VB
VT
DH
VB
KP
BP
AR
Overseen ByAhsun Riaz, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Merit Medical Systems, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of this drug for knee osteoarthritis?

Research shows that triamcinolone acetonide extended-release, a type of corticosteroid, significantly reduces pain and improves function in knee osteoarthritis patients compared to a placebo. It is formulated to release slowly, providing longer-lasting relief with fewer side effects.12345

Is GAE with Embosphere Microspheres for Knee Osteoarthritis safe?

Triamcinolone acetonide, a type of corticosteroid used in knee osteoarthritis, is generally well tolerated with a safety profile similar to placebo, though it can cause minor side effects like hypopigmentation (lightening of the skin) and should be administered carefully to avoid tissue damage. Intra-articular corticosteroid injections are widely used and can suppress joint inflammation with minimal systemic effects, but repeated injections should be limited to avoid potential cartilage damage.15678

What makes the drug GAE with Embosphere Microspheres unique for knee osteoarthritis?

This drug uses extended-release microspheres to slowly release corticosteroids directly into the knee joint, providing longer-lasting pain relief and reducing systemic side effects compared to standard corticosteroid injections.5691011

What is the purpose of this trial?

This multicenter, prospective, interventional trial is designed to assess the outcome of subjects with symptomatic knee osteoarthritis (OA) that are randomized to treatment with either genicular artery embolization (GAE) using Embosphere Microspheres or steroid injection over a period of 24 months.

Research Team

SB

Sandeep Bagla, MD

Principal Investigator

Prostate Centers, USA

CJ

Craig J McAsey, MD

Principal Investigator

Anderson Orthopedic Clinic

Eligibility Criteria

This trial is for adults over 21 with knee osteoarthritis who still have pain (score of ≥4 out of 10) despite trying other treatments for at least 3 months. It's not suitable for those planning major surgeries within a month, with advanced artery disease, previous knee replacement on the affected knee, or arthritis due to rheumatoid or infection.

Inclusion Criteria

I am 21 years old or older.
My pain hasn't improved with treatment for over 3 months.
Provides written informed consent
See 2 more

Exclusion Criteria

I have a history of rheumatoid or infectious arthritis.
I have advanced hardening of the arteries.
I have had a knee replacement surgery on the knee in question.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to receive either genicular artery embolization using Embosphere Microspheres or corticosteroid injection for knee osteoarthritis

6 months
Multiple visits for treatment and assessment

Follow-up

Participants are monitored for safety and effectiveness after treatment

18 months
Follow-up assessments at 3, 12, and 24 months

Treatment Details

Interventions

  • Corticosteroid injection
  • EmboSphere Microspheres
Trial Overview The study compares two treatments for knee osteoarthritis: genicular artery embolization (GAE) using Embosphere Microspheres and steroid injections. Participants will be randomly assigned to one treatment and followed up for two years to see which is more effective.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Genicular artery embolization with Embosphere MicrospheresExperimental Treatment1 Intervention
Device: Embosphere Microspheres Embolic Agent: Embosphere Microspheres
Group II: Corticosteroid Injection of the kneeActive Control1 Intervention
Drug: Corticosteroid injection

Corticosteroid injection is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Corticosteroids for:
  • Allergic reactions
  • Asthma
  • COPD
  • Rheumatoid arthritis
  • Osteoarthritis
  • Bursitis
  • Tendonitis
  • Skin conditions
  • Eye conditions
  • Gastrointestinal disorders
🇪🇺
Approved in European Union as Corticosteroids for:
  • Allergic reactions
  • Asthma
  • COPD
  • Rheumatoid arthritis
  • Osteoarthritis
  • Bursitis
  • Tendonitis
  • Skin conditions
  • Eye conditions
  • Gastrointestinal disorders
🇨🇦
Approved in Canada as Corticosteroids for:
  • Allergic reactions
  • Asthma
  • COPD
  • Rheumatoid arthritis
  • Osteoarthritis
  • Bursitis
  • Tendonitis
  • Skin conditions
  • Eye conditions
  • Gastrointestinal disorders

Find a Clinic Near You

Who Is Running the Clinical Trial?

Merit Medical Systems, Inc.

Lead Sponsor

Trials
35
Recruited
3,500+

Findings from Research

In a double-blind study involving 30 patients with rheumatoid arthritis, all three intra-articular steroid preparations (prednisolone t-butyl acetate, methyl prednisolone acetate, and triamcinolone hexacetonide) showed thermographic improvement in knee synovitis, with triamcinolone demonstrating the greatest and longest-lasting effect.
Despite the local improvements in knee symptoms, no significant overall systemic improvement was observed after a single injection of any steroid, although all three preparations suppressed the body's natural cortisol production.
A thermographic and clinical comparison of three intra-articular steroid preparations in rheumatoid arthritis.Bird, HA., Ring, EF., Bacon, PA.[2022]
In a study of 289 rheumatoid arthritis patients, intra-articular injection of triamcinolone hexacetonide showed significant improvement in pain, particularly in patients receiving injections in the elbow and metacarpophalangeal joints, as well as those with a functional class II status.
Long-term response predictors included being male, non-white, receiving polyarticular injections, and using a higher total dose of triamcinolone, indicating that specific demographic and treatment factors can influence the effectiveness of this therapy.
[Intra-articular injections of triamcinolone hexacetonide in rheumatoid arthritis: short and long-term improvement predictors].Furtado, RN., Machado, FS., Luz, KR., et al.[2017]
Intra-articular corticosteroid injections for knee osteoarthritis showed a mild to moderate effect on pain severity lasting up to 3 months, which is longer than previously reported, based on a review of eight randomized controlled studies with follow-ups ranging from 1 to 26 weeks.
The risk of adverse effects from these injections was low, indicating that they are a relatively safe option for managing knee osteoarthritis pain.
The Magnitude and Duration of the Effect of Intra-articular Corticosteroid Injections on Pain Severity in Knee Osteoarthritis: A Systematic Review and Meta-Analysis.Saltychev, M., Mattie, R., McCormick, Z., et al.[2021]

References

A thermographic and clinical comparison of three intra-articular steroid preparations in rheumatoid arthritis. [2022]
[Intra-articular injections of triamcinolone hexacetonide in rheumatoid arthritis: short and long-term improvement predictors]. [2017]
The Magnitude and Duration of the Effect of Intra-articular Corticosteroid Injections on Pain Severity in Knee Osteoarthritis: A Systematic Review and Meta-Analysis. [2021]
Intra-articular glucocorticoids in early juvenile chronic arthritis. [2019]
Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee. [2023]
Electron microscopic study of depot corticosteroid crystals with clinical studies after intra-articular injection. [2013]
Linear rays of hypopigmentation following intra-articular corticosteroid injection for post-traumatic degenerative joint disease. [2013]
[Intra-articular glucocorticoid injections in joint diseases]. [2017]
Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs. [2020]
Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). [2018]
Glucocorticoid resorption and influence on the hypothalamic-pituitary-adrenal axis after intra-articular treatment of the knee in resting and mobile patients. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security